OneMedNet Expands Access to Regulatory-Grade Imaging Data Through Strategic Partnerships
核心洞察
OneMedNet (搜索) has integrated its regulatory-grade imaging Real-World Data (搜索) (iRWD) into HealthVerity (搜索) Marketplace, providing access to over 121 million clinical exams from 31 million unique patients across 1,400 healthcare systems.
The collaboration with HealthVerity (搜索) enables seamless linkage of imaging data with de-identified medical claims, pharmacy data, and electronic health records, delivering more comprehensive patient journey insights for researchers.
OneMedNet (搜索) has also partnered with Datavant (搜索) to provide tokenized, purpose-built data for life sciences research, enhancing longitudinal data visibility while maintaining privacy compliance.
OneMedNet (搜索) Corporation (Nasdaq: ONMD) has significantly expanded access to its regulatory-grade imaging Real-World Data (搜索) (iRWD) through strategic partnerships with two leading health data platforms, positioning the company as a key player in the evolving healthcare data ecosystem.
HealthVerity Marketplace Integration Enhances Real-World Evidence Generation
OneMedNet (搜索) has joined HealthVerity (搜索) Marketplace™, making its extensive imaging data network discoverable and available within the nation's largest healthcare and consumer data ecosystem. This integration brings a powerful new data modality to researchers and life sciences companies seeking comprehensive patient insights.
The partnership provides access to OneMedNet (搜索)'s expansive iRWD network, which spans more than 1,400 healthcare systems and provider sites, encompassing over 121 million clinical exams from 31 million unique patients. This imaging data offers unique clinical insights that structured data alone cannot provide, including visual confirmation of disease progression, diagnostic markers, and therapeutic response patterns.
"The addition of OneMedNet (搜索)'s regulatory-grade imaging data into HealthVerity (搜索) Marketplace significantly enhances the depth of real-world data available to our clients," said Andrew Kress, CEO of HealthVerity. "We continue to expand the scope of what's possible using large-scale, data-driven evidence generation, allowing researchers to make more informed clinical development and commercialization decisions."
A key advantage of this integration is the ability to seamlessly link imaging data with de-identified real-world medical claims, pharmacy claims, laboratory results, and electronic health records. This comprehensive approach delivers a more complete and clinically nuanced view of the patient journey, supporting applications across clinical development, commercial strategy, and regulatory submissions.
Datavant Collaboration Expands Data Tokenization Capabilities
In a parallel development, OneMedNet (搜索) has also established a collaboration with Datavant (搜索), a health data platform company, to provide access to tokenized, purpose-built data for life sciences and medical research through Datavant's health data ecosystem.
This partnership integrates OneMedNet (搜索)'s patient tokens into Datavant (搜索)'s ecosystem of more than 300 real-world data partners. The collaboration enables life sciences companies to integrate claims data with OneMedNet's rich repository of EMR insights, including images, ECGs, and clinical notes, providing a comprehensive view of patient journeys tailored to specific disease states.
"Linking healthcare data securely unlocks transformative potential for researchers," said Aaron Green, President of OneMedNet (搜索). "Cross-referencing our data with existing datasets through the Datavant (搜索) ecosystem confirms its unique value, ensuring it's additive, non-redundant and cost-effective."
Implications for Clinical Research and Drug Development
The expanded availability of OneMedNet (搜索)'s imaging data through these partnerships addresses several critical challenges in healthcare research:
-
Enhanced Patient Journey Visibility: By connecting imaging data with other healthcare datasets, researchers gain unprecedented visibility into complete patient journeys, from initial diagnosis through treatment and outcomes.
-
Improved Clinical Trial Design: Access to comprehensive real-world data enables more precise protocol development and patient selection criteria, potentially reducing trial failures and accelerating development timelines.
-
Regulatory-Grade Evidence Generation: The high-quality, regulatory-grade nature of OneMedNet (搜索)'s data supports submissions to regulatory authorities, providing robust evidence for safety and efficacy claims.
-
Privacy-Protected Data Exchange: Both partnerships emphasize HIPAA-compliant, privacy-protected data exchange, addressing growing concerns about patient data security while enabling valuable research.
Expanding Applications Across Healthcare
OneMedNet (搜索)'s data integration capabilities extend beyond traditional clinical research. The company's proprietary AI technology anonymizes data for various industries, including finance, retail, and telecommunications, enabling secure sharing of sensitive information by removing personal identifiers.
For healthcare specifically, these partnerships open new possibilities for:
-
Rare disease (搜索) research: Accessing sufficient patient data has historically been challenging for rare conditions, but OneMedNet (搜索)'s extensive network helps overcome this limitation.
-
Oncology (搜索) insights: Imaging data provides crucial information about tumor characteristics and treatment response that may not be captured in structured data alone.
-
Cardiovascular (搜索) research: ECG data and cardiac imaging offer detailed insights into disease progression and treatment efficacy.
The integration of OneMedNet (搜索)'s imaging capabilities into these established data ecosystems represents a significant advancement in how healthcare researchers can access and utilize real-world data, potentially accelerating medical innovation and improving patient outcomes through more informed decision-making across the healthcare continuum.